No Data
TD Cowen Maintains ATAI Life Sciences(ATAI.US) With Buy Rating
TD Cowen analyst Ritu Baral maintains $ATAI Life Sciences(ATAI.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 44.1% and a total average return of 7.4% over the pa
Atai Life Sciences CEO Talks Successful Phase 1 Trial of IV Psilocin Formulation – ICYMI | NASDAQ:ATAI, ETR:9VC
Atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,
Atai Life Sciences Co-CEO Says Initial Results From ELE-101 Show Promise in Treating Depression | NASDAQ:ATAI, ETR:9VC
Cantor Fitzgerald Reiterates Overweight on ATAI Life Sciences
Cantor Fitzgerald analyst Charles Duncan reiterates ATAI Life Sciences (NASDAQ:ATAI) with a Overweight.
ATAI Life Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/21/2024 — Cantor Fitzgerald Reiterates → Overweight 05/17/2024 1049.43% HC Wainwright & Co. $15 → $15